{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:16:34Z","timestamp":1778721394536,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T00:00:00Z","timestamp":1367884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40259-013-0037-2","type":"journal-article","created":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T08:48:41Z","timestamp":1367830121000},"page":"401-406","source":"Crossref","is-referenced-by-count":13,"title":["Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares"],"prefix":"10.1007","volume":"27","author":[{"given":"Katherine A.","family":"Lyseng-Williamson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,7]]},"reference":[{"issue":"11","key":"37_CR1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2165\/11592290-000000000-00000","volume":"71","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs. 2011;71(11):1413\u20139.","journal-title":"Drugs"},{"key":"37_CR2","first-page":"39","volume":"4","author":"SR Kingsbury","year":"2011","unstructured":"Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39\u201349.","journal-title":"J Inflamm Res"},{"issue":"1","key":"37_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RHU.0b013e31827d8790","volume":"19","author":"BN Cronstein","year":"2013","unstructured":"Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013;19(1):19\u201329.","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"37_CR4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/11592750-000000000-00000","volume":"28","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Jordan S. The challenges of gout management in the elderly. Drug Aging. 2011;28(8):591\u2013603.","journal-title":"Drug Aging"},{"issue":"6 Suppl 1","key":"37_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3810\/pgm.2011.11.2511","volume":"123","author":"M Hamburger","year":"2011","unstructured":"Hamburger M, Baraf HS, Adamson TC 3rd, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 Suppl 1):3\u201336.","journal-title":"Postgrad Med"},{"issue":"2","key":"37_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semarthrit.2012.03.010","volume":"42","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155\u201365.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"37_CR7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"37_CR8","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"37_CR9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"37_CR10","unstructured":"Ilaris (canakinumab) 150\u00a0mg powder for solution for injection: summary of product characteristics. London: European Medicines Agency; 2013."},{"issue":"1","key":"37_CR11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/11208450-000000000-00000","volume":"26","author":"MP Curran","year":"2012","unstructured":"Curran MP. Canakinumab in patients with cryopyrin-associated periodic syndromes. Biodrugs. 2012;26(1):53\u20139.","journal-title":"Biodrugs"},{"issue":"1","key":"37_CR12","first-page":"81","volume":"11","author":"LD Church","year":"2009","unstructured":"Church LD, McDermott MF. Canakinumab, a fully human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11(1):81\u20139.","journal-title":"Curr Opin Mol Ther"},{"issue":"6","key":"37_CR13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1\u201318.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"37_CR14","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/ar2438","volume":"10","author":"R Alten","year":"2008","unstructured":"Alten R, Gram H, Joosten LA, et al. The human anti-IL-1\u03b2 monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R6.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"37_CR15","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839\u201348.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"37_CR16","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064\u201376.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"37_CR17","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","volume":"13","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13(2):R53.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"37_CR18","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard.2007.071530","volume":"66","author":"M Doherty","year":"2007","unstructured":"Doherty M, Bardin T, Pascual E. International survey on the diagnosis and management of gout. Ann Rheum Dis. 2007;66(12):1685\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"37_CR19","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"37_CR20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11926-010-0154-6","volume":"13","author":"NL Edwards","year":"2011","unstructured":"Edwards NL. Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep. 2011;13(2):154\u20139.","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"37_CR21","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","volume":"70","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264\u201371.","journal-title":"Ann Rheum Dis"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-013-0037-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-013-0037-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T10:20:50Z","timestamp":1595758850000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-013-0037-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,7]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1007\/s40259-013-0037-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,7]]}}}